NARCOLEPSY

被引:104
作者
MITLER, MM
HAJDUKOVIC, R
ERMAN, M
KOZIOL, JA
机构
[1] Sleep Disorders Center, Scripps Clinic and Research Foundation, La Jolla, CA
关键词
Central nervous system stimulants; Narcolepsy; Polysomnography; Tricyclic antide-pressants;
D O I
10.1097/00004691-199001000-00008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Narcolepsy is a neurological condition with a prevalence of up to 1 per 1,000 that is characterized by irresistible bouts of sleep. Associated features include the pathological manifestations of rapid-eye-movement (REM) sleep: cataplexy, sleep paralysis, hypnagogic hallucinations, and abnormal sleep-onset REM periods and disturbed nocturnal sleep. The condition is strongly associated with the HLA-DR2 and DQwl phenotype. The phenomenology of narcolepsy is discussed, and diagnostic procedures are reviewed. Treatment modalities involving central nervous system stimulants for somnolence and tricyclic drugs for REM-sleep abnormalities are discussed. Sleep laboratory studies on the treatment efficacy of methylphenidate, pemoline, dextroamphetamine, protriptyline, and viloxazine are presented. Data suggest that: (1) methylphenidate and dextroamphetamine objectively improve somnolence; (2) pemoline, at doses up to 112.5 mg, is less effective in controlling somnolence but may improve certain aspects of performance; and (3) protriptyline and viloxazine are effective anticataplectic agents that produce little improvement in somnolence. © 1990 American Electroencephalographic Society.
引用
收藏
页码:93 / 118
页数:26
相关论文
共 91 条
[1]  
Aserinsky E., Kleitman N., Regularly occurring periods of eye motility and concomitant phenomena during sleep, Science, 118, pp. 273-274, (1953)
[2]  
Committee on somnolent patients (Mitler MM, chairman). Resolution on reporting patients with excessive somnolence, Assoc Sleep Disord Cent Newslett, 2, pp. 14-16, (1984)
[3]  
Diagnostic classification of sleep and arousal disorders prepared by the sleep disorders classification committee (Roffwarg HP, chairman), Sleep, 2, pp. 1-137, (1979)
[4]  
Baker T., Foutz A., McNerney V., Mitler M., Dement W., Canine model of narcolepsy: Genetic and developmental determinants, Exp Neurol, 75, pp. 729-742, (1982)
[5]  
Baldy-Moulinier M., Arguner A., Basset A., Ultradian and circadian rhythms in sleep and wakefulness, Narcolepsy, 3, pp. 485-488, (1976)
[6]  
Baxter B., Induction of both emotional behavior and a novel form of REM sleep by chemical stimulation applied to cat mesencephalon, Exp Neurol, 23, pp. 220-229, (1969)
[7]  
Boehme R., Baker T.L., Mefford I., Ciaranello R., Dement W., Muscarinic cholinergic receptor abnormalities in canine narcolepsy, Sleep Res, 2, (1982)
[8]  
Broughton R., Ghanem Q., The impact on compound narcolepsy in the life of the patient, Narcolepsy, 3, pp. 201-220, (1976)
[9]  
Broughton R., Mamalak M., Gamma-hydroxy-butyrate in the treatment of narcolepsy: A preliminary report, Narcolepsy, 3, pp. 659-667, (1976)
[10]  
Browman C., Gujavarty K., Sampson M., Mitler M., REM sleep episodes during the maintenance of wakefulness test in patients with sleep apnea syndrome and patients with narcolepsy, Sleep, 6, pp. 23-28, (1983)